EIK1004 (IMP1707)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for EIK1004 (IMP1707), covering 2025-08-19 to 2025-08-19. Get the full timeline:
Most recent: Clinical Trial Update: A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. [Phase 1, Phase 2]